



Xellia Pharmaceuticals appoints Preben Haaning to its Board of Directors



Copenhagen, Denmark, 22 March 2021 - Xellia Pharmaceuticals ('Xellia'), a global leader in the manufacturing of specialty anti-infective treatments, has appointed Preben Haaning to its Board of Directors.

Preben Haaning is currently Senior Vice President of Product Supply Biopharm at Novo Nordisk, responsible for large and small molecule drug substance and drug product manufacturing and managing the supply of biologics for the treatment of rare blood and endocrine disorders.

Preben joined Novo Nordisk in 1999 as an Industrial Engineer. He has held various roles, including responsibility for supervising 5 manufacturing sites located in US, Brazil, France, China and Denmark. Preben is in addition elected to the Novo Nordisk Haemophilia Foundation Council.

Preben will replace Per Valstorp who is retiring from his position on the Board of Directors after serving for 8 years.

Steen Riisgaard, Chairman of the Board at Xellia Pharmaceuticals, commented:

"Preben has a strong track record in managing pharmaceutical manufacturing and supply operations. We are confident that his background and expertise will bring great value to Xellia, with particular emphasis on our anti-infective manufacturing sites. I would also like to take the opportunity to thank Per Valstorp for his service on our Board of Directors and wish him all the best for his retirement."

Preben Haaning, newly appointed Board member, added: *"I look forward to supporting Xellia's leadership team in their efforts to provide a reliable supply of critical anti-infective products to hospitals and patients globally. I followed the acquisition and development of their Cleveland manufacturing facility with great interest and recognize its importance in providing critical care products to markets in the US and beyond. I believe Xellia's focus on a responsible manufacturing of essential anti-infectives, plays a vital role in society."*

Prior to his work in pharmaceutical manufacturing, Preben Haaning served as Platoon Leader for the United Nations Peace Keeping Force in Cyprus, as well as First Lieutenant in the Royal Danish Army.

Preben graduated as an Industrial Engineer from the Danish Technical University and holds an Organizational Development diploma from the Copenhagen Business School.

- Ends -

For more information, please contact:

Xellia Pharmaceuticals

Carl-Åke Carlsson, CEO

Tel: +45 32 64 55 00

Instinctif Partners (International media relations)

Melanie Toyne-Sewell / Rozi Morris / Siobhan Sanford

Tel: +44 (0) 20 7457 2020

Email: xellia@instinctif.com

About Xellia Pharmaceuticals

Xellia Pharmaceuticals (“Xellia”) is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections.

With over 115 years of experience, Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as injectable products. Continuing the Company’s evolution, Xellia is generating an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience and ease of use for healthcare professionals.

Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia, the Middle East and North America. Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of over 1,800 people.

Further information about Xellia can be found at: www.xellia.com. Connect with us on [LinkedIn](#).